Replies to post #2161 on PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[Spideyboy]

Thanks again for your input here. Much appreciated.

Agreed, given what I think is great results from Phase II studies in both Pegunigalsidase and DNAse, and the new Cheisi deal, I think now is a good time to buy.

Also in case anyone is interested, I did quite a bit of desk research into the science behind OPRX-106 for Ulcerative Colitis and except for one area that I can't be very clear on the science checks out and fits quite beautifully with OPRX-106 design.

In a brief explanation:

The platform makes the anti-TNF product inside carrot plant cells. These carrot plant cells are vascular plant cells that can't be broken down by our digestive system. Therefore the cells pass though the stomach acids, bile, and small intestine unaffected. These zones have different acidic or alkaline levels. However, once they reach the large intestine/colon, the acidity reaches around neutral pH levels and that is why the bacterial flora grow and live there. The bacteria in the large intestine/colon can breakdown the cellulose cell wall of vascular plant cells, thereby releasing the anti-TNF drug into the large intestine, hence being released in the exact location of the body affected in Ulcerative Colitis.

This I understand is one reason why PLX chose to go for the Ulcerative colitis indication, as it have the production platform itself allows specific benefits.

The only other way to treat Ulcerative Colitis with anti-TNF is by IV infusion which is both, less targeted and more inconvenient.

I'm not sure if the cost would be much lower than other anti-TNF treatment given the totality of the dosage as the oral formulation is given daily, over time isn't too much lower than the intermittent IV dosage. But perhaps also an added advantage PLX has here is the efficiency of anti-TNF production that can also allow us to undercut the competition. However of course PLX will want to keep the cost just under current prices I assume and let convenience, improved targeting and hopefully positive clinical data do the selling.